Ipsen ((GB:0MH6)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
In a recent update, Ipsen is conducting a study titled Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS). This study aims to observe the long-term effectiveness and safety of odevixibat (Bylvay) in patients with ALGS, a rare liver disease. The study is significant as it seeks to provide real-world insights into the drug’s performance over time.
The intervention being tested is odevixibat, a medication designed to alleviate symptoms of Alagille Syndrome, particularly liver damage and itching. This drug is intended to improve the quality of life for patients suffering from this rare condition.
The study is observational in nature, focusing on real-world data collection over a two-year period. It employs a prospective time perspective, meaning it will follow patients forward in time to gather data on the drug’s effectiveness and safety.
The study began on February 13, 2025, with a primary completion date yet to be determined. The latest update was submitted on August 27, 2025, indicating ongoing recruitment and data collection efforts.
For investors, this study could influence Ipsen’s stock performance positively if the results demonstrate significant benefits of odevixibat. It could enhance investor sentiment and position Ipsen favorably against competitors in the rare disease treatment market.
The study is currently ongoing, with further details accessible on the ClinicalTrials portal.